Search clinical trials for: Influenza Vaccine Recipients

Total 6594 results

Seqirus

Completed

Phase II Study of Pandemic Influenza Vaccine

Influenza

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009

Interpandemic Influenza

Italy
Crucell Holland BV

Completed

Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains

Influenza

Switzerland
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

Influenza

Poland
Bayer
CureVac

Withdrawn

COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older (CV-NCOV-011)

Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
Vanderbilt-Ingram Cancer Center

Completed

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

Adult Stem Cell Hematopoetic Transplant

United States
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Hoffmann-La Roche

Completed

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Canada, United States
Jiangsu Province Centers for Disease Control and...

Completed

Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

COVID-19

China
Duke University
Centers for Disease Control and Prevention; Kaiser Permanente

Completed

Fever After Simultaneous Versus Sequential Vaccination in Young Children

Fever | Febrile Seizure | Fever After Vaccination

United States
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine

Vaccine Reaction | Influenza | Influenza, Human | Vaccination; Infection | Influenza Viral Infections

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Safety and Immunogenicity of Fluzone® in Healthy Children

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

France
Celgene

Completed

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Germany
University of Pennsylvania
National Institute of Allergy and Infectious Diseases (NIAID); Stanford University and other collaborators

Recruiting

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

Influenza, Human

United States
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Enrolling by invitation

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

Influenza

China
University of Wisconsin, Madison

Completed

VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT) (VACC-HeFT)

Chronic Heart Failure

United States
brian.ward
MedTeq; MEDICAL INTERNATIONAL TECHNOLOGIES (MIT CANADA) INC.

Completed

Comparison of Routine IM Influenza Immunization and Administration by Jet-injector (Med-Jet H4™) in Healthy Young Adults (Med-Jet H4™)

Needle Phobia

Canada
Novartis Vaccines
Novartis Vaccines and Diagnostics (formerly Chiron Vaccines)

Completed

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

Influenza Disease; Flu

United States
Seqirus

Completed

Study of a Pandemic Influenza Vaccine

Influenza

Australia
Centers for Disease Control and Prevention, China

Completed

Persistence of Immune Response After Vaccination With Influenza Vaccine

Influenza, Human | Immunisation Reaction

China
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects

Influenza

Italy
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

Influenza

Korea, Republic of
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate

Influenza

Belgium
University of Birmingham
Wellcome Trust; University Hospital Birmingham NHS Foundation Trust

Unknown

Investigating the Immune System in chrONIC Kidney Disease. (SONIC)

Immune System Diseases | Chronic Kidney Disease

United Kingdom
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above

Influenza

Korea, Republic of
UMN Pharma Inc.

Completed

Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza | Vaccine

Japan
UMN Pharma Inc.

Completed

Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Influenza

United States
Fluart Innovative Vaccine Ltd, Hungary

Completed

Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine

Influenza

Hungary
GlaxoSmithKline

Completed

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Influenza

Korea, Republic of
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants

Dengue

Thailand
Donald T. Weed, MD, FACS

Completed

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States
Shahid Beheshti University of Medical Sciences

Completed

Antibody Response to Influenza Vaccine in Patients With Sarcoidosis (IVS)

Pulmonary Sarcoidosis

Iran, Islamic Republic of
National Institute of Allergy and Infectious Diseases...

Terminated

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

Influenza | Influenza Immunisation

United States
Gilead Sciences

Terminated

Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib

B-cell Malignancies

Spain, Czechia
Sanofi Pasteur, a Sanofi Company

Completed

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

Pregnancy | Influenza

United States
Mark Prausnitz
Emory University

Completed

Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle

Influenza

United States
Emory University

Completed

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination (FLU1)

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules

Influenza

Taiwan, Hong Kong, Thailand, Singapore
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season (FluMist)

Healthy | Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects

Prepandemic Influenza Vaccine

Hungary
Novartis Vaccines

Completed

Immunogenicity and Safety of V70P5 Revaccination Subjects

Influenza

Finland
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season (FluMist)

Healthy | Influenza

United States
Altimmune, Inc.

Completed

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Influenza A Subtype H5N1 Infection

United States
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Healthy | Influenza

United States

3

Subscribe